Evaluation of New Biomarkers in Stage 3 and 4 Endometriosis

Study Overview
=================
Brief Summary
-----------------
The diagnostic value of Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and Proinflammatory cytokines (TNF-a and interleukin-6) in ovarian endometriosis and deep infiltrating endometriosis, their levels in organ-specific involvement, their relationship with symptoms, and the changes of these markers in the postoperative period will be evaluated.

Detailed Description
-----------------
Serum Annexin V, sVCAM-1, sICAM-1, vascular endothelial growth factor and proinflammatory cytokines (TNF-a and interleukin-6) values were studied by taking blood samples from all patients before and three months after the operation.

Official Title
-----------------
Diagnostic Value of Annexin V, sVCAM-1, sICAM-1, Vascular Endothelial Growth Factor, TNF Alpha and Interleukin-6 in Ovarian and Deep Infiltrating Endometriosis, the Changes of These Markers in the Postoperative Period

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Procedure: endometriosis surgery
* Procedure: other benign condition surgeries


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Stage III and IV endometriosis patients requiring surgery due to chronic pelvic pain or suspected malignancy Exclusion Criteria: Malignant disease Ovarian failure Acute pelvic inflammatory disease Smokers Pregnancy Chronic autoimmune disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Group<br>Stage 3 and 4 endometriosis patients | Procedure: endometriosis surgery<br>* Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.<br>|
| Control Group<br>Patients without endometriosis, who required surgery for tubal ligation, benign ovarian cysts or uterine fibroids were included. | Procedure: other benign condition surgeries<br>* ovarian cystectomy, bilateral tubal ligation, myomectomy etc.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic value of serum Annexin V in endometriosis | To determine whether serum Annexin V levels (ng/mL) can be used as diagnostic markers of endometriosis disease. | Up to 4 months | 
| Diagnostic value of serum sVCAM-1 in endometriosis | To determine whether serum sVCAM-1(ng/mL) levels can be used as diagnostic markers of endometriosis disease. | Up to 4 months | 
| Diagnostic value of serum sICAM-1 in endometriosis | To determine whether serum sICAM-1(ng/mL) levels can be used as diagnostic markers of endometriosis disease. | Up to 4 months | 
| Diagnostic value of serum Vascular Endothelial Growth Factor in endometriosis | To determine whether serum Vascular Endothelial Growth Factor (pg/mL) levels can be used as diagnostic markers of endometriosis disease. | Up to 4 months | 
| Diagnostic value of serum TNF-alpha in endometriosis | To determine whether serum TNF-alpha (pg/mL) levels can be used as diagnostic markers of endometriosis disease. | Up to 4 months | 
| Diagnostic value of serum Interleukin-6 in endometriosis | To determine whether serum Interleukin-6 (pg/mL) levels can be used as diagnostic markers of endometriosis disease. | Up to 4 months |